HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Thomas A. Orszulak Hartzell V. Schaff Charles J. Mullany Francisco J. Puga Gordon K. Danielson Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orszulak, T. A. Articles by Danielson, G. K. Search for Related Content PubMed PubMed Citation Articles by Orszulak, T. A. Articles by Danielson, G. K.

Ann Thorac Surg 1995;59:462-468
© 1995 The Society of Thoracic Surgeons

Risk of Thromboembolism With the Aortic Carpentier-Edwards Bioprosthesis

Sections of Cardiovascular Surgery and Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

Accepted for publication October 14, 1994.

Porcine bioprostheses provide an excellent alternative to mechanical prostheses for heart valve replacement in patients unable to comply with systemic anticoagulation and in the elderly. Long-term results of this prosthesis, however, demonstrated identical survival and parallel event-free status, albeit at a lower rate than the mechanical valves. Some discrepancy exists as to the need for and duration of systemic anticoagulation in the bioprosthesis, and some evidence exists to contraindicate anticoagulation due to a higher late mortality rate in patients with an aortic bioprosthesis. The records of 561 patients having the Carpentier-Edwards bioprosthesis in the aortic position as an isolated valve procedure were reviewed. The overall rate of bioprosthetic failure events was low (0.23%/patient year) and the survival (5 year, 74.8 ± 2.4%; 10 year, 52.9 ± 4.9%) and event-free statistics (5 year, 67.9 ± 2.6%; 10 year, 42.4 ± 5.1%) were excellent. No gender difference was present. A vulnerable period for neurologic events was identified by hazard function whereby the incidence of stroke was high; these were increased in the patient variables of compromised ejection fraction (0.54; p 0.003), older age (73 years; p 0.02), and preoperative atrial fibrillation or paced rhythm (p 0.01). This pattern was similar for both transient ischemic events and strokes and rapidly decreased over the first few months of the first year and the first few years of the 12-year follow-up. These patients were not routinely anticoagulated. Although, in general, patients receiving a bioprosthesis in the aortic position do not require anticoagulants, a subset of patients have been identified who should receive short-term anticoagulation in an attempt to reduce the high early incidence of neurologic events.

This article has been cited by other articles:

				A. Colli, J.-P. Verhoye, A. Leguerrier, and T. Gherli Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 573 - 577. [Abstract] [Full Text] [PDF]

				J. Nowell, E. Wilton, H. Markus, and M. Jahangiri Antithrombotic therapy following bioprosthetic aortic valve replacement Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 578 - 585. [Abstract] [Full Text] [PDF]

				O. Lund and M. Bland Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement J. Thorac. Cardiovasc. Surg., July 1, 2006; 132(1): 20 - 26. [Abstract] [Full Text] [PDF]

				J P A Puvimanasinghe, J J M Takkenberg, M B Edwards, M J C Eijkemans, E W Steyerberg, L A van Herwerden, K M Taylor, G L Grunkemeier, J D F Habbema, and A J J C Bogers Comparison of outcomes after aortic valve replacement with a mechanical valve or a bioprosthesis using microsimulation Heart, October 1, 2004; 90(10): 1172 - 1178. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF]

				T. Gherli, A. Colli, C. Fragnito, F. Nicolini, B. Borrello, S. Saccani, R. D'Amico, and C. Beghi Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement: A Prospective Study Circulation, August 3, 2004; 110(5): 496 - 500. [Abstract] [Full Text] [PDF]

				M. Ruel, R. G. Masters, F. D. Rubens, P. J. Bedard, A. L. Pipe, W. G. Goldstein, P. J. Hendry, and T. G. Mesana Late incidence and determinants of stroke after aortic and mitral valve replacement Ann. Thorac. Surg., July 1, 2004; 78(1): 77 - 83. [Abstract] [Full Text] [PDF]

				T. A. Orszulak Invited commentary Ann. Thorac. Surg., October 1, 2002; 74(4): 1113 - 1114. [Full Text] [PDF]

				T. A. Orszulak, H. V. Schaff, F. J. Puga, G. K. Danielson, C. J. Mullany, B. J. Anderson, and D. M. Ilstrup Event Status of the Starr-Edwards Aortic Valve to 20 Years: A Benchmark for Comparison Ann. Thorac. Surg., March 1, 1997; 63(3): 620 - 626. [Abstract] [Full Text]